BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance.
"We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a significant layer of strength that will be integral to the company's continued success."
"I am thrilled with my new role and the ability to work alongside Maria and the leadership team to advance Annovis at such a pivotal time. We will be working collaboratively to position the Company to achieve its goals," said Mr. Walsh.
Mr. Walsh joins Annovis from Ocugen, a clinical stage biotechnology ...